-
公开(公告)号：US11547667B2
公开(公告)日：2023-01-10
申请号：US16544464
申请日：2019-08-19
申请人： Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , President and Fellows of Harvard College , The Children's Medical Center Corporation
发明人： Ulrich H. von Andrian , Omid C. Farokhzad , Robert S. Langer , Tobias Junt , Elliott Ashley Moseman , Liangfang Zhang , Pamela Basto , Matteo Iannacone , Frank Alexis
摘要： The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.
-
公开(公告)号：US11446239B2
公开(公告)日：2022-09-20
申请号：US17024148
申请日：2020-09-17
发明人： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
摘要： Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US10729818B2
公开(公告)日：2020-08-04
申请号：US15588475
申请日：2017-05-05
发明人： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC分类号： A61L29/08 , A61K47/36 , A61K9/48 , A61K35/39 , C08B37/00 , A61K9/00 , A61K9/50 , A61L31/10 , A61L33/08 , C07D487/04 , C12N5/00 , C12N5/071
摘要： Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US20190254975A1
公开(公告)日：2019-08-22
申请号：US16403183
申请日：2019-05-03
IPC分类号： A61K9/16 , C12N5/071 , A61L27/54 , A61K31/573 , A61K45/06 , A61K35/39 , G01N33/50 , A61L27/38 , A61K9/00 , A61L27/52 , A61L27/48
摘要： A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US20190091139A1
公开(公告)日：2019-03-28
申请号：US16200334
申请日：2018-11-26
发明人： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
摘要： Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US20190046690A9
公开(公告)日：2019-02-14
申请号：US15341118
申请日：2016-11-02
摘要： Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
-
公开(公告)号：US20180353650A1
公开(公告)日：2018-12-13
申请号：US16007922
申请日：2018-06-13
CPC分类号： A61L27/3834 , A61K9/0024 , A61L27/16 , A61L27/34 , A61L27/38 , A61L27/52 , A61L29/041 , A61L31/048 , C08F20/18 , C08F2438/01 , C08L33/26 , C08L2203/02
摘要： Macrodevices containing a micro-fabricated body having at least one or multiple compartments and a porous membrane, methods of making and using thereof, are described. The one or multiple compartments encapsulate one or more cells that secrete a therapeutic agent in cell-based therapy. The porous membrane provides immunoprotection the encapsulated cells. Further, the surface of the macrodevices is chemically modified using polymers and/or small molecules, reducing fibrosis of the macrodevices, thereby allowing in vivo delivery of the secreted therapeutic agents for extended periods of time.
-
公开(公告)号：US20180353643A1
公开(公告)日：2018-12-13
申请号：US15573926
申请日：2016-05-17
发明人： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Arturo Jose Vegas , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup
CPC分类号： A61L27/20 , A61F2/02 , A61F2230/0071 , A61F2240/001 , A61F2250/0068 , A61L27/3804 , A61L27/52 , A61L27/54 , A61L2300/64 , A61L2400/18 , A61M31/002 , A61M2205/04 , A61M2207/00
摘要： Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US09994615B2
公开(公告)日：2018-06-12
申请号：US14379477
申请日：2013-02-19
摘要： A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia.
-
公开(公告)号：US09724447B2
公开(公告)日：2017-08-08
申请号：US14286743
申请日：2014-05-23
申请人： Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , The Children's Medical Center Corporation
发明人： Jeffrey M. Karp , Pedro del Nido , Nora Lang , Robert S. Langer , Maria Jose M. N. Pereira , Yuhan Lee
IPC分类号： A61L24/00 , A61L24/04 , C08G63/91 , A61L15/58 , C08G63/47 , A61L15/26 , A61L15/42 , C08F222/10
CPC分类号： A61L24/046 , A61L15/26 , A61L15/42 , A61L15/58 , A61L24/001 , A61L2400/18 , C08F2222/1073 , C08G63/47 , C08G63/914 , C08L67/04
摘要： Pre-polymers for use as tissue sealants and adhesives, and methods of making and using thereof are provided. The pre-polymers have flow characteristics such that they can be applied through a syringe or catheter but are sufficiently viscous to remain in place at the site of application and not run off the tissue. The pre-polymers are also sufficiently hydrophobic to resist washout by bodily fluids. The pre-polymers are stable in bodily fluids; that is the pre-polymer does not spontaneously crosslink in bodily fluids absent the presence of an intentionally applied stimulus to initiate crosslinking. Upon crosslinking, the adhesive exhibits significant adhesive strength in the presence of blood and other bodily fluids. The adhesive is sufficiently elastic that it is able to resist movement of the underlying tissue. The adhesive can provide a hemostatic seal. The adhesive is biodegradable and biocompatible, causing minimal inflammatory response.
-
-
-
-
-
-
-
-
-
搜索结果
366 条记录 (耗时 0.211 秒)
